top of page

ASH 2024: Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma

Dec 7, 2024
1 min read

CEO Will West describes how the company focuses on inhibiting the bromodomain of these targets with inobrodib, rather than the active sites, and how this is different than the approaches of other companies. He describes CellCentric's phase 2 data at ASH and the next steps for the program.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Mispro_Logo_2023_Primary-4.png

Mispro is an AAALAC-accredited contract vivarium organization (CVO) offering a network of full-service vivarium rental lab facilities for preclinical in vivo rodent studies. Along with access to state-of-the-art lab spaces, Mispro supports its clients with comprehensive laboratory animal research services, including husbandry, veterinary, technical, and regulatory compliance oversight. With locations in all major U.S. biotech hubs, Mispro is committed to helping biosciences companies of all sizes and therapeutic indications achieve their research goals.

bottom of page